Skip to main content

Chronic Lymphocytic Leukaemia

5
Pipeline Programs
9
Companies
8
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
457%
Small Molecule
343%
+ 2 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Fortrea
FortreaDURHAM, NC
1 program
1
AcalabrutinibPhase 4Small Molecule1 trial
Active Trials
NCT06651970Recruiting60Est. Aug 2030
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
OfatumumabPhase 3Monoclonal Antibody
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
surovatamigPhase 33 trials
Active Trials
NCT07509151Recruiting420Est. Apr 2032
NCT07571746Recruiting43Est. Oct 2029
NCT07201558Recruiting48Est. Jun 2028
Bayer
BayerLEVERKUSEN, Germany
1 program
1
Rituximab-CHOP-AlemtuzumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT00504491Withdrawn0Est. Jun 2012
NovalGen
NovalGenUK - Northwood Hills
1 program
1
NVG-111Phase 11 trial
Active Trials
NCT04763083Unknown90Est. Dec 2025
Kite Pharma
Kite PharmaCA - El Segundo
1 program
IdelalisibN/ASmall Molecule1 trial
Active Trials
NCT03582098Completed112Est. Mar 2019
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
1 program
IdelalisibN/ASmall Molecule
Chugai Pharma
Chugai PharmaJapan - Tokyo
1 program
OfatumumabPHASE_3Monoclonal Antibody1 trial
Active Trials
NCT01678430Unknown670Est. Dec 2017
GSK
GSKLONDON, United Kingdom
1 program
OfatumumabPHASE_3Monoclonal Antibody

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
FortreaAcalabrutinib
AstraZenecasurovatamig
Chugai PharmaOfatumumab
AstraZenecasurovatamig
BayerRituximab-CHOP-Alemtuzumab
AstraZenecasurovatamig
NovalGenNVG-111
Kite PharmaIdelalisib

Clinical Trials (8)

Total enrollment: 1,443 patients across 8 trials

NCT06651970FortreaAcalabrutinib

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

Start: Feb 2025Est. completion: Aug 203060 patients
Phase 4Recruiting
NCT07509151AstraZenecasurovatamig

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

Start: May 2026Est. completion: Apr 2032420 patients
Phase 3Recruiting
NCT01678430Chugai PharmaOfatumumab

A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment

Start: Dec 2011Est. completion: Dec 2017670 patients
Phase 3Unknown
NCT07571746AstraZenecasurovatamig

A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease

Start: Mar 2026Est. completion: Oct 202943 patients
Phase 2Recruiting
NCT00504491BayerRituximab-CHOP-Alemtuzumab

R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia

Start: Jul 2007Est. completion: Jun 20120
Phase 2Withdrawn
NCT07201558AstraZenecasurovatamig

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

Start: Dec 2025Est. completion: Jun 202848 patients
Phase 1Recruiting
NCT04763083NovalGenNVG-111

First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

Start: May 2021Est. completion: Dec 202590 patients
Phase 1Unknown
NCT03582098Kite PharmaIdelalisib

Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland

Start: Sep 2018Est. completion: Mar 2019112 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
4 actively recruiting trials targeting 1,443 patients
Monoclonal Antibody is the dominant modality (57% of programs)
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.